Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04561154
Other study ID # CHM-2020/S10/04
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 11, 2020
Est. completion date June 11, 2022

Study information

Verified date March 2022
Source Centre Hospitalier le Mans
Contact Christelle JADEAU
Phone 0243434343
Email cjadeau@ch-lemans.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Since December 2019, China and then the rest of the world have been affected by the rapid spread of a new coronavirus infection called SARS-CoV-2 (severe acute respiratory syndrome coronavirus), the clinical expression of which is called Covid-19 (Coronavirus Disease 2019). It is estimated that around 20% of symptomatic patients will be severe enough to warrant hospitalization, of which around 5% will be in intensive care. Organ damage is multiple in Covid infection: respiratory, digestive, renal, neurological, cardiovascular due to the infection or its care. There is also a psychological and social impact of the infection or of the care that should be measured. In this context, investigator will assess the physical and psychological complaints of patients who have presented a severe form of SARS-CoV-2 infection. The final objective being to identify the needs to offer follow-up adapted to this emerging pathology.


Recruitment information / eligibility

Status Recruiting
Enrollment 134
Est. completion date June 11, 2022
Est. primary completion date June 11, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient hospitalized for severe Covid-19 infection between March 1 and June 30, 2020 in a conventional unit, intensive care unit, at the Centre hospitalier du Mans and alive at the time of the investigation at 2 to 3 months - Patient having given their express consent, after having received the research information letter upon discharge from hospital or having given their express consent after sending the information letter - Age = 18 years - Patient having contracted a SARS-CoV-2 infection proved by RT-PCR and / or retrospective serology and / or a Covid-19 syndrome with suggestive chest scanner (during the period from March 1, 2020 to June 30, 2020) Exclusion Criteria: - Patient opposition to participate in the cohort - Non-French speaking patient - Patients who cannot read or write - Patient subject to a protective measure - Patient not affiliated to a social security or equivalent health insurance

Study Design


Related Conditions & MeSH terms


Intervention

Other:
questionnaire
three months after hospitalization, a questionnaire will be sent to patients. If necessary, patient will be seen in consultation of geriatry, otorhinolaryngology, pneumology, neuropsychology

Locations

Country Name City State
France Centre Hospitalier du Mans Le Mans

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier le Mans

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identify functionnal and psychosocial complaints the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by questionnaire "Modified Medical Research Council" 3 months after last hospitalization
Primary Identify functionnal and psychosocial complaints the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by questionnaire "Medical Outcome Study Short Form 36 (MOS SF-36)" 3 months after last hospitalization
Primary Identify functionnal and psychosocial complaints the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by FRIED criteria 3 months after last hospitalization
Primary Identify functionnal and psychosocial complaints the prevalence of functional complaints and psycho-social complaints (justifying additional investigations in patients hospitalized for Covid-19 infection 3 months maximum after discharge from hospital) will be assessed by questionnaire "Hospital Anxiety and Depression Scale (HADS)" 3 months after last hospitalization
Secondary description of functionnal and psychosocial complaints complaints will be assessed by questionnaire "Modified Medical Research Council" 3 months after last hospitalization
Secondary description of functionnal and psychosocial complaints complaints will be assessed by questionnaire "Medical Outcome Study Short Form 36 (MOS SF-36)" 3 months after last hospitalization
Secondary description of functionnal and psychosocial complaints complaints will be assessed by FRIED criteria 3 months after last hospitalization
Secondary description of functionnal and psychosocial complaints complaints will be assessed by questionnaire "Hospital Anxiety and Depression Scale (HADS)" 3 months after last hospitalization
Secondary Identify the factors favoring the persistence of complaints Risk factors are defined according to age, concomitant treatment, comorbidities before hospitalization 3 months after last hospitalization
Secondary Describe functional, neuropsychological and social complaints at a distance Complaints will be assessed by questionnaire"Modified Medical Research Council" 3 months after last hospitalization
Secondary Describe functional, neuropsychological and social complaints at a distance Complaints will be assessed by questionnaire"Medical Outcome Study Short Form 36 (MOS SF-36)" 3 months after last hospitalization
Secondary Describe functional, neuropsychological and social complaints at a distance Complaints will be assessed by FRIED criteria 3 months after last hospitalization
Secondary Describe functional, neuropsychological and social complaints at a distance Complaints will be assessed by questionnaire "Hospital Anxiety and Depression Scale (HADS)" 3 months after last hospitalization
Secondary Describe the needs for medical and surgical consultations after discharge from hospital Medical and surgical consultations after discharge will be measured as percentage 3 months after last hospitalization
Secondary Describe the needs for neuropsychological support, dietetics, social assistance after discharge from hospital. neuropsychological support, dietetics, social assistance after discharge will be measured as percentage 3 months after last hospitalization
Secondary Describe the factors of inequalities in access to care Describe the factors of inequalities in access to care and study their impact on the occurrence of a SARS-CoV-2 infection, its severity and the occurrence of a functional or psycho-social complaint. 3 months after last hospitalization
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3